Oculus Launches Microcyn Solution

The Microcyn Solution for professional use is intended for the irrigation and management via debridement of post-surgical wounds. Available in 500ml and 990ml units with attached pharmasling hangers, Microcyn Solution has no known drug/treatment interactions or contraindications, is non-foaming and safe to use around nose, mouth and eyes. It does not contain antibiotics and will not facilitate bacterial resistance, claims the company.

With a laboratory-proven inactivation of bacteria, fungus and spores in-solution, Microcyn delivers a six-log reduction of MRSA, VRE, Pseudomonas, Acinetobacter and many other pathogens in 30 seconds as labeled and cleared by the FDA.

The company said that the patented Microcyn Solution can be easily and harmlessly disposed of.

Adam Landsman, assistant professor of surgery at Harvard Medical School in Boston, said: “The current standard for surgical wound cleansing and irrigation involves the use of products that do not kill the MRSA infection in-vitro. This is important in light of the skyrocketing proliferation of these dangerous bacteria as well as the evolving ‘super bug’ mutations.

“Microcyn is also highly attractive since it does not produce foam, which hampers visualization of the wound. And finally, with the health community so vitally focused on cost savings, the Microcyn Solution will actually cost less than the current combination of saline and expensive antibiotics.”